Pharmacist Resources
POMALYST® (pomalidomide), in combination with dexamethasone, is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
POMALYST REMS® information for certified pharmacies
POMALYST is only dispensed from POMALYST REMS® program certified pharmacies.
As a POMALYST REMS® certified pharmacy, you must follow the requirements of the POMALYST REMS®
program. You may download a guide to the program, a checklist for counseling patients, and the full
prescribing information below.
The Celgene REMS Pharmacy Portal
In addition to calling the Celgene Customer Care Center to obtain a confirmation number for a prescription, eligible pharmacies can obtain confirmation numbers using the Celgene REMS Pharmacy Portal at CelgeneREMSPharmacyPortal.com. Contact your Celgene Account Manager to see if your pharmacy is eligible.
Please report adverse drug experiences that are suspected to be associated with the use of POMALYST
and any suspected pregnancy occurring during the treatment with POMALYST to Celgene using any of the
following methods:
REPORTING TO CELGENE |
|
Online: |
|
Email: |
|
Telephone: 1-908-673-9667 |
|
Toll-free: 1-800-640-7854 (Global Drug Safety & Risk Management) or |
|
Fax: 1-908-673-9115 |
|
Mail to: Global Drug Safety & Risk Management |
|
Other: Per individual agreement between the reporting organization and Celgene Global Drug Safety & Risk Management |
REPORTING TO THE FDA |
|
Adverse drug experiences that are suspected to be associated with the use of POMALYST and
|
|
Online: |
|
Telephone: 1-800-FDA-1088 |
|
Fax: 1-800-FDA-0178 |
|
Mail to: MedWatch |
For additional information about the POMALYST REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436
POMALYST® and POMALYST REMS® are registered trademarks of Celgene Corporation.
© 2013-2017. Celgene Corporation, www.celgene.com.
This website is intended for residents of the United States only.
